The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL539495     6-(imidazol-1-ylmethyl)- 5,6,7,8...

Synonyms: SureCN7301697, DP-1904, LS-94531, AC1L41PX, 97901-22-9, ...
This record was replaced with 65851.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of DP 1904

  • OBJECTIVE: To examine abnormalities of prostanoid metabolism in lupus nephritis, which may affect renal function, and the effects of 4 day dosing of a selective thromboxane A2 (TXA2) synthetase inhibitor, DP-1904, on prostanoid metabolism [1].
  • CONCLUSION: The abnormal prostanoid metabolism observed in lupus nephritis could aggravate renal function, which was mediated hemodynamically, and the altered metabolism was reversible and at least partially corrected by a TXA2 synthetase inhibitor, DP-1904 [1].
  • These findings suggested that DP-1904 improved renal failure by specifically inhibiting TXA2 production [2].
  • These results suggest that DP-1904 may be an effective agent for the treatment of proliferative glomerulonephritis [3].
  • When the treatment was started from the 22nd day, at which time proteinuria is fully developed, DP-1904 showed beneficial effects on proteinuria and glomerular histopathological changes [4].

High impact information on DP 1904


Biological context of DP 1904


Anatomical context of DP 1904


Associations of DP 1904 with other chemical compounds


Gene context of DP 1904

  • DP-1904 and an internal standard were extracted from plasma and urine by means of a Sep-Pak C18 cartridge [11].
  • The mean percent inhibition by 10 microM DP-1904 was 49 +/- 10 and 31 +/- 2 against PAF and IgG-induced ECP release, respectively [12].
  • The effects of four days' dosing of a selective thromboxane A2 (TXA2) synthetase inhibitor, DP-1904 (DP), on prostanoid metabolism, were also studied [16].

Analytical, diagnostic and therapeutic context of DP 1904

  • In isolated perfused hydronephrotic rat kidneys, DP-1904 suppressed the increase in perfusion pressure and TXB2 production caused by platelet-activating factor [2].
  • The method was applied to the determination of DP-1904 in plasma and urine samples from a normal human volunteer who had received a 200-mg oral dose of the drug [11].
  • In the platelet-deprived animal, DP-1904 showed further significant inhibition of the constriction and plasma TXA2 level, and therefore likely inhibits TXA2 synthesis of various cells, including platelets, in the bloodstream [17].


  1. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis. Yoshida, T., Kameda, H., Ichikawa, Y., Tojo, T., Homma, M. J. Rheumatol. (1996) [Pubmed]
  2. A thromboxane A2 synthase inhibitor, DP-1904, prevents rat renal injury. Masumura, H., Kunitada, S., Irie, K., Ashida, S., Abe, Y. Eur. J. Pharmacol. (1991) [Pubmed]
  3. Effect of DP-1904, a thromboxane A2 synthetase inhibitor, on crescentic nephritis in rats. Nagao, T., Ito, M., Nagamatsu, T., Suzuki, Y. Eur. J. Pharmacol. (1994) [Pubmed]
  4. Effect of DP-1904, a thromboxane A2 synthase inhibitor, on passive Heymann nephritis in rats. Nagao, T., Nagamatsu, T., Suzuki, Y. Eur. J. Pharmacol. (1996) [Pubmed]
  5. Effect of DP-1904, a thromboxane synthetase inhibitor, on antigen- and spasmogen-induced bronchoconstriction in rodents. Takami, M., Tsukada, W. Eur. J. Pharmacol. (1999) [Pubmed]
  6. In vitro responses to antigen stimulation: comparison between human lung parenchyma resected from asthmatic patients and non-asthmatic patients. Fukushima, C., Shimoda, T., Matsuse, H., Matsuo, N., Takao, A., Obase, Y., Asai, S., Ayabe, H., Kohno, S. Ann. Allergy Asthma Immunol. (1999) [Pubmed]
  7. DP-1904, a specific inhibitor of thromboxane A2 synthesizing enzyme, suppresses ICAM-1 expression by stimulated vascular endothelial cells. Ishizuka, T., Suzuki, K., Kawakami, M., Kawaguchi, Y., Hidaka, T., Matsuki, Y., Nakamura, H. Eur. J. Pharmacol. (1994) [Pubmed]
  8. A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy. Masumura, H., Kunitada, S., Irie, K., Ashida, S., Abe, Y. Eur. J. Pharmacol. (1992) [Pubmed]
  9. The pharmacokinetics and pharmacodynamics of a new thromboxane synthetase inhibitor, 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904), in man after single oral administration. Tanaka, M., Ono, K., Takegoshi, T., Shiozawa, T., Suzuki, T., Nii, S., Shibata, H. J. Pharm. Pharmacol. (1989) [Pubmed]
  10. Pharmacokinetic-pharmacodynamic modelling of DP-1904, a novel thromboxane synthetase inhibitor in rabbits, based on an indirect response model. Zheng, N.X., Sato, H., Adachi, I., Horikoshi, I. European journal of drug metabolism and pharmacokinetics. (1996) [Pubmed]
  11. Determination of the thromboxane synthetase inhibitor 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904) in human plasma and urine using solid-phase extraction and high-performance liquid chromatography. Tanaka, M., Ono, K., Takegoshi, T. J. Chromatogr. (1988) [Pubmed]
  12. A novel thromboxane synthetase inhibitor, DP-1904, inhibits human blood eosinophil degranulation. Agrawal, D.K., Takami, M., Ono, S. Inflammation (1997) [Pubmed]
  13. Effects of DP-1904, a thromboxane synthetase inhibitor, on the antigen-induced airway hyperresponsiveness and infiltration of inflammatory cells in guinea-pigs. Takami, M., Tsukada, W. Prostaglandins Leukot. Essent. Fatty Acids (1998) [Pubmed]
  14. Thromboxane A2 synthase inhibitor, DP-1904, decreases TNF alpha secretion from monocytes and inhibits E-selectin and ICAM-1 expression on the endothelial cell surfaces. Kameda, H., Yoshida, T., Ichikawa, Y., Homma, M. Adv. Prostaglandin Thromboxane Leukot. Res. (1995) [Pubmed]
  15. Identification of DP-1904 and its ester glucuronide in human urine and determination of their enantiomeric compositions by high-performance liquid chromatography with optical activity and ultraviolet detection. Tanaka, M., Ono, K., Hakusui, H., Takegoshi, T., Watanabe, Y., Kanao, M. Drug Metab. Dispos. (1990) [Pubmed]
  16. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904. Yoshida, T., Ichikawa, Y., Tojo, T., Homma, M. Lupus (1996) [Pubmed]
  17. Correlative alteration of thromboxane A2 with antigen-induced bronchoconstriction and the role of platelets as a source of TXA2 synthesis in guinea pigs: effect of DP-1904, an inhibitor of thromboxane synthetase. Takami, M., Tsukada, W. Pharmacol. Res. (1998) [Pubmed]
WikiGenes - Universities